Daamouch Souad, Diendorfer Andreas, Hackl Matthias, Christoffel Gabriele, Hofbauer Lorenz C, Rauner Martina
Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany.
TAmiRNA, Vienna, Austria.
Front Endocrinol (Lausanne). 2024 Dec 24;15:1477257. doi: 10.3389/fendo.2024.1477257. eCollection 2024.
Type 1 diabetes (T1D) represents a significant health burden worldwide, with associated complications including bone fragility. Current clinical methods and biomarkers for assessing bone health and predicting fracture risk in T1D are limited and lack accuracy. MicroRNAs (miRNAs) have emerged as potential biomarkers for predicting T1D-induced bone loss, although comprehensive profiling studies are lacking. Previous investigations have indicated a link between dysregulated miRNA expression levels and impaired bone health in T1D. Therefore, in this study, we explored differential miRNA expression levels in serum and bone tissue of mice with T1D-induced bone loss using Next Generation Sequencing (NGS). T1D was induced using streptozotocin in male wild-type mice. Serum and bone tissues were analyzed at 14 weeks of age, following the prior characterization of bone loss in this mouse model. MiRNA profiling was conducted using two-independent NGS analyses and validated through quantitative RT-PCR. NGS profiling identified differential expression of miRNAs in serum and bone tissue of T1D mice compared to controls. The first NGS analysis revealed 24 differentially expressed miRNAs in serum and 13 in bone tissue. Especially, miR-136-3p was consistently downregulated in both serum and bone tissue. However, the second NGS analysis presented a distinct set of dysregulated miRNAs, with miR-206-3p overlapping in both tissues but exhibiting differential expression patterns. Surprisingly, miR-144-5p, miR-19a-3p, and miR-21a-5p displayed contrasting regulatory patterns between NGS and qPCR analyses. Finally, gene network analysis identified associations between dysregulated miRNAs and pathways involved in bone physiology, including TGF-beta, PI3-Akt signaling, and osteoclast differentiation in humans. In conclusion, our study offers initial insights into dysregulated miRNAs associated with T1D-induced bone loss, but also highlights the lack of consistency in the results obtained from miRNA sequencing in different cohorts. Thus, further investigation is needed to better understand the complexities of miRNA analyses before they can be established as reproducible biomarkers for predicting bone health in T1D.
1型糖尿病(T1D)是全球范围内一项重大的健康负担,其相关并发症包括骨质脆弱。目前用于评估T1D患者骨骼健康状况及预测骨折风险的临床方法和生物标志物十分有限,且缺乏准确性。微小RNA(miRNA)已成为预测T1D所致骨质流失的潜在生物标志物,不过仍缺乏全面的分析研究。此前的调查表明,T1D患者中miRNA表达水平失调与骨骼健康受损之间存在关联。因此,在本研究中,我们使用下一代测序(NGS)技术,探究了T1D诱导的骨质流失小鼠血清和骨组织中miRNA的差异表达水平。通过对雄性野生型小鼠注射链脲佐菌素诱导T1D。在该小鼠模型骨质流失特征确定后,于14周龄时对血清和骨组织进行分析。使用两次独立的NGS分析进行miRNA分析,并通过定量逆转录聚合酶链反应(qRT-PCR)进行验证。NGS分析确定了与对照组相比,T1D小鼠血清和骨组织中miRNA的差异表达。首次NGS分析显示血清中有24种差异表达的miRNA,骨组织中有13种。特别地,miR-136-3p在血清和骨组织中均持续下调。然而,第二次NGS分析呈现出一组不同的失调miRNA,miR-206-3p在两种组织中均有重叠,但表达模式不同。令人惊讶的是,miR-144-5p、miR-19a-3p和miR-21a-5p在NGS和qPCR分析之间显示出相反的调控模式。最后,基因网络分析确定了失调的miRNA与人类骨骼生理相关通路之间的关联,包括转化生长因子-β(TGF-β)、磷脂酰肌醇-3激酶(PI3-Akt)信号传导和破骨细胞分化。总之,我们的研究初步揭示了与T1D诱导的骨质流失相关的失调miRNA,但也凸显了不同队列中miRNA测序结果缺乏一致性的问题。因此,在将其确立为预测T1D患者骨骼健康的可重复生物标志物之前,需要进一步研究以更好地理解miRNA分析的复杂性。